Semaglutide Weight Management and Cardiovascular Risk Reduction
Insulin icodec showed superiority in both patient reported
outcomes endpoints vs daily basal insulins in ONWARDS 5
DTSQ total treatment score: Health-related quality of life questionnaire
Treatment satisfaction score: 1-6
TRIM-D compliance domain score: Compliance questionnaire
Treatment satisfaction score: 1-100
4.68
Treatment difference
0.781
3.90
90.42
Treatment difference
3.042
87.37
Once-weekly insulin icodec
Once-daily basal insulin analogues
Once-weekly insulin icodec.
Once-daily basal insulin analogues
Estimated mean change from baseline
Estimated mean difference at week 52
1Treatment difference = 0.78 [0.10;1.47]95% CI, P value: 0.0247
2Treatment difference = 3.04 [1.28;4.81]95% CI, P value: 0.0007
DTSQ: Diabetes Treatment Satisfaction Questionnaire; TRIM-D: Treatment-Related Impact Measure Diabetes
Note: Insulin icodec was in combination with a dosing guide app. Once- daily basal insulin analogues include insulin degludec and insulin glargine U100 and U300View entire presentation